https://doi.org/10.4081/reumatismo.2022.1483

Clinical profile of patients with lupus psychosis in a Colombian cohort

Vol. 74 No. 2 (2022)
Submitted: 7 February 2022
Accepted: 15 May 2022
Published: 13 September 2022
Neuropsychiatric lupus, systemic lupus erythematosus, psychosis.
Abstract Views: 1074
PDF: 488
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M. Muñoz-Urbano
marcela.munoz2@udea.edu.co
Rheumatology Group, University of Antioquia (GRUA), Medellín, Colombia.
J. Sánchez-Bautista
Department of Internal Medicine, University of Antioquia Antioquia, Medellín, Colombia.
A. Ramirez
Department of Internal Medicine, University of Antioquia Antioquia, Medellín, Colombia.
D.C. Quintero-González
Rheumatology Group, University of Antioquia (GRUA), Medellín, Colombia.
Y. Santamaria-Alza
Rheumatology Group, University of Antioquia (GRUA), Medellín, Colombia.
A.L. Vanegas-García
Rheumatology Group, University of Antioquia (GRUA), Medellín, Colombia; Hospital San Vicente Fundación, Medellín, Colombia.

The objective of this study is to describe the frequency and the clinical, paraclinical, and treatment profile of patients with lupus psychosis in a Colombian cohort of patients with systemic lupus erythematosus (SLE). This retrospective cohort study evaluated epidemiological and clinical characteristics, results of neuroimaging, analysis of the cerebrospinal fluid, treatment, and disease evolution in patients with lupus psychosis. Among 2,479 patients with SLE, six female patients aged between 20 and 50 years with a diagnosis of lupus psychosis were identified. In two patients, psychosis was present at disease onset and in the other four, SLE was already present, although the majority of them were diagnosed less than two years prior to the onset of psychosis. The entire cohort had high disease activity as measured by SLEDAI-2K. We found concomitant cutaneous, joint, and hematological alterations. Cerebrospinal fluid data were obtained in half of the patients and were normal. We performed brain tomography on most of our patients, which was almost always described as normal. In 5 out of 6 patients, the induction therapy to treat psychosis was based on steroids, and in the majority of them, a resolution of psychiatric symptoms was observed after initiating treatment. Lupus psychosis is a rare event that usually occurs early in the course of the disease and is associated with other manifestations of SLE. This investigation mainly found concomitant cutaneous, joint, and hematological manifestations, with a favorable outcome after treatment, as described in the literature.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Hanly JG, Li Q, Su L, Urowitz MB, Gordon C, Bae SC, et al. Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2019; 71: 281-89. DOI: https://doi.org/10.1002/art.40764
Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: Characteristics and long-term outcome of this rare disease manifestation. Rheumatology. 2008; 47: 1498-502. DOI: https://doi.org/10.1093/rheumatology/ken260
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999; 42: 599-608.
Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010; 69: 2074-82. DOI: https://doi.org/10.1136/ard.2010.130476
Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007; 56: 265-73. DOI: https://doi.org/10.1002/art.22305
Hanly JG, Urowitz MB, Su L, et al. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 2008; 59: 721-29. DOI: https://doi.org/10.1002/art.23566
Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29: 288-91.
Appenzeller S, Cendes F, Costallat LTL. Acute psychosis in systemic lupus erythematosus. Rheumatol Int. 2008; 28: 237-43. DOI: https://doi.org/10.1007/s00296-007-0410-x
Kumar P, Kumar A, Thakur V, et al. Acute psychosis as the presenting manifestation of lupus. J Fam Med Prim Care. 2021; 10: 1050-3. DOI: https://doi.org/10.4103/jfmpc.jfmpc_1475_20
[No authors listed]. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther. 1972; 13: 694-98. DOI: https://doi.org/10.1002/cpt1972135part1694
Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006; 81: 1361-67. DOI: https://doi.org/10.4065/81.10.1361
Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med. 1987; 317: 265-71. DOI: https://doi.org/10.1056/NEJM198707303170503
Hirohata S, Kanai Y, Mitsuo A, et al. Differential characteristics of lupus psychosis and steroid psychosis. Proceedings of the 2018 ACR/ARHP Annual Meeting; 2018 Oct 21; Chicago (IL). Arthritis Rheumatol. 2018; 70 (suppl 10). DOI: https://doi.org/10.1002/art.40700
Viana VT, Durcan L, Bonfa E, Elkon KB. Ribosomal P antibody: 30 years on the road. Lupus. 2017; 26: 453-62. DOI: https://doi.org/10.1177/0961203317690243
Hanly JG. Avoiding diagnostic pitfalls in neuropsychiatric lupus: The importance of attribution. Lupus. 2017; 26: 497-503. DOI: https://doi.org/10.1177/0961203317690244
Nayak RB, Bhogale GS, Patil NM, Chate SS. Psychosis in patients with systemic lupus erythematosus. Indian J Psychol Med. 2012; 34: 90-3. DOI: https://doi.org/10.4103/0253-7176.96170
Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209-23. DOI: https://doi.org/10.1056/NEJMoa051688

How to Cite

Muñoz-Urbano, M., Sánchez-Bautista, J., Ramirez, A., Quintero-González, D. ., Santamaria-Alza, Y., & Vanegas-García, A. (2022). Clinical profile of patients with lupus psychosis in a Colombian cohort. Reumatismo, 74(2). https://doi.org/10.4081/reumatismo.2022.1483
Copyright (c) 2022 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Similar Articles

You may also start an advanced similarity search for this article.